Skip to main content
Evidence Snapshot

LIM domain kinase 2

CHEMBL5932 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5932
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats LIM domain kinase 2 as ChEMBL target CHEMBL5932, mapped to UniProt P53671. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
LIM domain kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5932
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53671
LIM domain kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why LIM domain kinase 2 matters

As of 2026-09-13

LIM domain kinase 2 is reviewed as LIM domain kinase 2 (UniProt P53671); the current evidence base includes 10 approved drugs, 814 compounds, and 177 assays, with lead potency reaching pChEMBL 10.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 814 compounds, and 177 assays for this target. The dominant activity type is KD. CHEMBL3797519 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL3797519 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why LIM domain kinase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P53671, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

814
Total Compounds
177
Total Assays
10
Approved Drugs
IC50: 348.0, KI: 46.0, EC50: 2.0, KD: 372.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3797519
 10.0 IC50 —
No preferred name
CHEMBL3800458
 10.0 IC50 —
No preferred name
CHEMBL3799318
 10.0 IC50 —
No preferred name
CHEMBL3800259
 9.7 IC50 —
No preferred name
CHEMBL3798142
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
CAPIVASERTIB
CHEMBL2325741
 2023
ENCORAFENIB
CHEMBL3301612
 2018
DABRAFENIB
CHEMBL2028663
 2013
CRIZOTINIB
CHEMBL601719
 2011
PAZOPANIB
CHEMBL477772
 2009
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5932